COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03363776
Recruitment Status : Active, not recruiting
First Posted : December 6, 2017
Last Update Posted : June 11, 2020
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to investigate experimental medication BMS-986277 given alone and in combination with Nivolumab in patients with epithelial cancers.

Condition or disease Intervention/treatment Phase
Cancer Biological: BMS-986277 Biological: Nivolumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors
Actual Study Start Date : November 24, 2017
Actual Primary Completion Date : November 22, 2019
Estimated Study Completion Date : December 29, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Monotherapy
BMS-986277 administered alone
Biological: BMS-986277
Specified dose on specified days

Experimental: Combination Dose Escalation Therapy
BMS-986277 administered in combination with Nivolumab
Biological: BMS-986277
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-963558

Experimental: Combination Expansion Therapy
BMS-986277 monotherapy with option for subsequent Nivolumab therapy
Biological: BMS-986277
Specified dose on specified days

Biological: Nivolumab
Specified dose on specified days
Other Names:
  • Opdivo
  • BMS-963558

Primary Outcome Measures :
  1. Number of adverse events (AE) [ Time Frame: Up to 842 days ]
  2. Number of serious adverse events (SAE) [ Time Frame: Up to 842 days ]
  3. Number of AEs meeting dose limiting toxities criteria [ Time Frame: Up to 842 days ]
  4. Number of AEs leading to discontinuation [ Time Frame: Up to 842 days ]
  5. Number of AEs resulting in death [ Time Frame: Up to 842 days ]
  6. Incidence of clinical laboratory test abnormalities [ Time Frame: Up to 842 days ]
  7. Incidence of vital sign abnormalities [ Time Frame: Up to 842 days ]

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 24 weeks ]
  2. Disease control rate (DCR) [ Time Frame: 24 weeks ]
  3. Median duration of response (mDOR) [ Time Frame: Up to 2 years ]
  4. Median progression-free survival (mPFS) [ Time Frame: Up to 24 weeks ]
  5. Progression-free survival (PFS) [ Time Frame: Up to 24 weeks ]
  6. Maximum observed blood concentration (Cmax) [ Time Frame: Up to 92 days ]
  7. Time of maximum observed blood concentration (Tmax) [ Time Frame: Up to 92 days ]
  8. Area under the blood concentration-time curve from time zero to time of last quanitifiable concentration [AUC(0-T)] [ Time Frame: Up to 92 days ]
  9. Area under the blood concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] [ Time Frame: Up to 92 days ]
  10. Apparent terminal half-life (T-HALF) [ Time Frame: Up to 92 days ]
  11. Total body clearance (CLT) [ Time Frame: Up to 92 days ]
  12. Volume of distribution at steady-state (Vss) [ Time Frame: Up to 92 days ]
  13. Volume of distribution of the elimination phase (Vz) [ Time Frame: Up to 92 days ]
  14. Average plasma concentration over a dosing interval (AUC[0-48]/48) (Css-avg) [ Time Frame: Up to 92 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

  • Histological or cytological confirmation of metastatic and/or unresectable metastatic colorectal, prostate, pancreatic, breast, ovarian, or urothelial carcinoma with measureable disease for solid tumors per RECIST v1.1 and for prostate carcinoma per PCWG3
  • Presence of at least 2 lesions: at least one with measurable disease as defined by RECIST v1.1 for solid tumors and by PCWG3 for prostate carcinoma for response assessment; at least 1 lesion must be accessible for biopsy in addition to the target lesion
  • Participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting, if such a therapy exists, and have been considered for all other potentially efficacious therapies prior to enrollment
  • ECOG performance status less than or equal to 2

Exclusion Criteria:

  • Participants with active central nervous system (CNS) metastases, untreated CNS metastases, or with the CNS as the only site of disease
  • Participants with carcinomatous meningitis
  • Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study treatment
  • Participants with active, known, or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03363776

Layout table for location information
United States, South Dakota
Sanford Research
Sioux Falls, South Dakota, United States, 57104
Canada, Ontario
Local Institution
Ottawa, Ontario, Canada, K1H 8L6
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1Z5
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT03363776    
Other Study ID Numbers: CA034-001
2017-002199-24 ( EudraCT Number )
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents